Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain - PubMed (original) (raw)
. 1995 Jan 26;373(6512):339-41.
doi: 10.1038/373339a0.
Affiliations
- PMID: 7830767
- DOI: 10.1038/373339a0
Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain
K D Beck et al. Nature. 1995.
Abstract
Glial-cell-line-derived neurotrophic factor (GDNF) promotes survival of embryonic dopaminergic neurons in culture, and its expression pattern suggests a role as a transient target-derived trophic factor for dopaminergic neurons of the substantia nigra. These neurons participate in the control of motor activity, emotional status and cognition, and they degenerate in Parkinson's disease for unknown reasons. To test whether GDNF has a trophic effect on dopaminergic neurons in the adult brain, we used a rat model in which these neurons are induced to degenerate by transecting their axons within the medial forebrain bundle. We report here that axotomy resulted in loss of half the tyrosine hydroxylase-expressing neurons in the substantia nigra. This loss was largely prevented by repeated injections of GDNF adjacent to the substantia nigra. Our findings suggest that GDNF or related molecules may be useful for the treatment of Parkinson's disease.
Comment in
- Neuron saving schemes.
Lindsay RM. Lindsay RM. Nature. 1995 Jan 26;373(6512):289-90. doi: 10.1038/373289a0. Nature. 1995. PMID: 7830762 No abstract available.
Similar articles
- Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections.
Kozlowski DA, Connor B, Tillerson JL, Schallert T, Bohn MC. Kozlowski DA, et al. Exp Neurol. 2000 Nov;166(1):1-15. doi: 10.1006/exnr.2000.7463. Exp Neurol. 2000. PMID: 11031079 - Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson's disease.
Grondin R, Gash DM. Grondin R, et al. J Neurol. 1998 Nov;245(11 Suppl 3):P35-42. doi: 10.1007/pl00007744. J Neurol. 1998. PMID: 9808338 Review. - Glutamate transport and metabolism in dopaminergic neurons of substantia nigra: implications for the pathogenesis of Parkinson's disease.
Plaitakis A, Shashidharan P. Plaitakis A, et al. J Neurol. 2000 Apr;247 Suppl 2:II25-35. doi: 10.1007/pl00007757. J Neurol. 2000. PMID: 10991662 Review.
Cited by
- Failure of Glial Cell-Line Derived Neurotrophic Factor (GDNF) in Clinical Trials Orchestrated By Reduced NR4A2 (NURR1) Transcription Factor in Parkinson's Disease. A Systematic Review.
Kambey PA, Kanwore K, Ayanlaja AA, Nadeem I, Du Y, Buberwa W, Liu W, Gao D. Kambey PA, et al. Front Aging Neurosci. 2021 Feb 24;13:645583. doi: 10.3389/fnagi.2021.645583. eCollection 2021. Front Aging Neurosci. 2021. PMID: 33716718 Free PMC article. - GDNF secreted from adipose-derived stem cells stimulates VEGF-independent angiogenesis.
Zhong Z, Gu H, Peng J, Wang W, Johnstone BH, March KL, Farlow MR, Du Y. Zhong Z, et al. Oncotarget. 2016 Jun 14;7(24):36829-36841. doi: 10.18632/oncotarget.9208. Oncotarget. 2016. PMID: 27167204 Free PMC article. - Overexpression of GDNF in Spinal Cord Attenuates Morphine Analgesic Tolerance in Rats with Bone Cancer Pain.
Xu W, Ding Z, Song Z, Wang J, Zhang J, Zou W. Xu W, et al. Brain Sci. 2022 Sep 3;12(9):1188. doi: 10.3390/brainsci12091188. Brain Sci. 2022. PMID: 36138924 Free PMC article. - Glial-derived neurotrophic factor is essential for blood-nerve barrier functional recovery in an experimental murine model of traumatic peripheral neuropathy.
Dong C, Helton ES, Zhou P, Ouyang X, d'Anglemont de Tassigny X, Pascual A, López-Barneo J, Ubogu EE. Dong C, et al. Tissue Barriers. 2018;6(2):1-22. doi: 10.1080/21688370.2018.1479570. Epub 2018 Sep 5. Tissue Barriers. 2018. PMID: 29913111 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources